Over the past decade, a gravity-assisted valve (GAV) has become a standard device in many European pediatric hydrocephalus centers. Because past comparative clinical outcome studies on valve design have not included any GAV, the authors in this trial evaluated the early results of GAV applications in a pediatric population.
For a minimum of 2 years the authors monitored 169 of 182 hydrocephalic children who received a pediatric GAV at their first CSF shunt insertion (61.5%) or as a substitute for any differential pressure valve (38.5%) at 1 of 7 European pediatric hydrocephalus centers. Outcomes were categorized as valve survival (primary outcome) or shunt survival (secondary outcome). The end point was defined as valve explantation.
Within a follow-up period of 2 years, the valve remained functional in 130 (76.9%) of 169 patients. One hundred eight of these patients (63.9%) had an uncomplicated clinical course without any subsequent surgery, and 22 (13%) were submitted to a valve-preserving catheter revision without any further complications during the follow-up period. Thirty-nine patients (23.1%) reached an end point of valve explantation: 13 valve failures from infection (7.7%), 8 (4.7%) from overdrainage, and 18 (10.6%) from underdrainage.
Compared with nongravitational shunt designs, a GAV does not substantially affect the early complication rate. Valve-preserving shunt revisions do not increase the risk of subsequent valve failure and therefore should not be defined as an end point in studies on valve design. A significant impact of any well-established valve design on the early complication rate in shunt surgery is not supported by any current data; therefore, this correlation should be dismissed. As overdrainage-related complications have been shown to occur late, the presumed advantages of a pediatric GAV remain to be shown in a long-term study.
Abbreviation used in this paper: GAV = gravity-assisted valve.
Address correspondence to: Ernst Johannes Haberl, Priv.Doz. Dr. med., Selbständiger Arbeitsbereích Pädiatrische Neurochirurgie der Charité, Charité Campus Virchow, D-13344 Berlin, Germany. email:
AschoffAKremerPBeneschCFruhKKlankAKunzeS: Overdrainage and shunt technology. A critical comparison of programmable, hydrostatic and variable-resistance valves and flow-reducing devices. Childs Nerv Syst11:193–2021995
AschoffA, KremerP, BeneschC, FruhK, KlankA, KunzeS: Overdrainage and shunt technology. A critical comparison of programmable, hydrostatic and variable-resistance valves and flow-reducing devices. 11:193–202, 1995)| false
HanloPWCinalliGVandertopWPFaberJOJBogeskovLBorgesenSE: Treatment of hydrocephalus determined by the European Orbis Sigma valve II survey: a multicenter prospective 5-year shunt survival study in children and adults in whom a flow-regulating shunt was used. J Neurosurg99:52–572003
HanloPW, CinalliG, VandertopWP, FaberJOJ, BogeskovL, BorgesenSE, : Treatment of hydrocephalus determined by the European Orbis Sigma valve II survey: a multicenter prospective 5-year shunt survival study in children and adults in whom a flow-regulating shunt was used. 99:52–57, 2003)| false